Skip to main content

Market Overview

Combining AstraZeneca, mRNA COVID-19 Vaccines Show Efficacy In Danish Study: Reuters

Combining AstraZeneca, mRNA COVID-19 Vaccines Show Efficacy In Danish Study: Reuters
  • Combining AstraZeneca plc's (NASDAQ: AZN) COVID-19 vaccine with a second dose from either Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) or Moderna Inc's (NASDAQ: MRNAshot provides "good protection," Denmark's State Serum Institute (SSI) said.
  • More than 144,000 Danish citizens, mostly healthcare frontline personnel and the elderly, received their first jab from AstraZeneca and subsequent shot from either Pfizer-BioNTech or Moderna, reports Reuters.
  • "The study shows that fourteen days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88% compared to unvaccinated individuals," the SSI said.
  • That is a "high efficacy," SSI added, comparable to the 90% efficacy rate of two doses from Pfizer-BioNTech's vaccine, confirmed in a different Danish study. But the study could not conclude whether the same protection applied to the Delta-variant.
  • It also provided no efficacy data on COVID-19 related deaths or hospitalizations since none took place following the combined vaccination program.
  • Price Action: AZN shares are up 0.31% at $57.42 on the last check Monday.
  • Photo by Johaehn from Pixabay

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: Briefs COVID-19 Vaccine ReutersBiotech News Health Care General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at